

# Diabetes And Depression Study

<b>Submission date</b> 04/01/2006	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered
<b>Registration date</b> 20/01/2006	<b>Overall study status</b> Completed	<input checked="" type="checkbox"/> Protocol
<b>Last Edited</b> 27/04/2015	<b>Condition category</b> Nutritional, Metabolic, Endocrine	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Prof Frank Petrak

**Contact details**  
Clinic of Psychosomatic Medicine and Psychotherapy  
LWL-University Clinic Bochum  
Ruhr-University Bochum  
Alexandrinenstr. 1-3  
Bochum  
Germany  
44791  
+49 (0)611 174 7841  
mail@dr-frank-petrak.de

## Additional identifiers

**Clinical Trials Information System (CTIS)**  
2005-004525-26

**Protocol serial number**  
01KG0505

## Study information

**Scientific Title**

## Diabetes And Depression Study

### Acronym

DAD

### Study objectives

Study hypotheses: As of 11/11/2010 this record has been updated based on an amendment from 12/11/2008; all updates can be found in the relevant section with the above update date. At this time the target number of participants was decreased from 304 - 230.

Current hypothesis as of 11/11/2010 due to the amendment of 12/11/2008:

A diabetes-specific cognitive behavioural therapy (CBT) leads to a clinically important improvement of glycaemic control when compared with sertraline. This is then measured by a one-year follow-up in patients who initially responded to short-term therapy (CBT or sertraline) with regards to improvement in depression.

Initial information at time of registration:

A diabetes-specific cognitive behavioural therapy (CBT) leads to a greater proportion of patients achieving clinically important improvement of glycaemic control when compared with sertraline. This is then measured by a one-year follow-up in patients who initially responded to short-term therapy (CBT or sertraline) with regards to improvement in depression.

On 12/11/2008 the target number of participants was changed from 304 to 230.

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Ethics approval received from the local Medical Ethics Committee (Ethik-Kommission der Landesärztekammer Hessen) on the 21st February 2006 (EudraCT: 2005-004525-26). Last amendment approved on 12/11/2008.

### Study design

Multicentre randomised controlled trial

### Primary study design

Interventional

### Study type(s)

Treatment

### Health condition(s) or problem(s) studied

Type 1 or type 2 diabetes mellitus

### Interventions

Please note that as of 08/05/2008 the anticipated end date of this trial was extended. The previous anticipated end date of this trial was 31/01/2009.

1. Ten sessions (20 hours) of diabetes-specific CBT in an outpatient setting within a 12-week time period. This treatment will comprise of manualised semi-structured standard CBT for depression. In addition, it will include diabetes-specific aspects. Cognitive and behavioural

techniques (cognitive restructuring, stress management, cueing) are used in this intervention to help patients diminish diabetes-related distress, reduce perceived barriers to various aspects of self-management, and enhance coping skills. The aim is to improve self-care behaviour and consequently improve glycaemic control.

2. Anti-depressive medication, with the selective serotonin reuptake inhibitor (SSRI) sertraline. Sertraline will be started at 50 mg per day in the morning. If no clinical response is achieved within 2-4 weeks, the dose may be raised to 100 mg per day in the morning. Further dose escalation is possible up to 200 mg per day at the clinician's discretion with changes not more rapidly than 50 mg per week.

After 12 weeks of open-label therapy, only the treatment-responders, showing 50% improvement of depression, in both groups will be included in the one-year long-term phase of the study.

In the long-term phase, diabetological treatment as usual will be given to both groups. CBT-responders will receive no further treatment, while patients responding to Selective Serotonin Reuptake Inhibitor (SSRI) will be given a sustained sertraline regimen as a relapse prevention.

### **Intervention Type**

Mixed

### **Primary outcome(s)**

Current information as of 11/11/2010 due to the amendment of 12/11/2008:

Change of glycaemic control (difference in HbA1c value from baseline to the end of the long term phase).

Initial information at time of registration:

Improvement of glycaemic control (minimum 1% decrease in glycosylated haemoglobin A1c test [HbA1c value]) from baseline.

### **Key secondary outcome(s)**

Current information as of 11/11/2010 due to the amendment of 12/11/2008:

1. "Improvement of glycaemic control" defined as a decrease of at least 1% in HbA1c value from baseline to the end of the long-term phase
2. Remission of depression, not fulfilling the DSM-IV-TR criteria for depression according to the Structured Clinical Interview Diagnosis (SCID) and depression score Hamilton Rating Scale (HAMD) Interview less than or equal to 7
3. Improvement of depression, i.e. a reduction of the HAMD-score from baseline to the end of study by at least 50%
4. Change from baseline to end of study in generic HRQoL as assessed per SF-36
5. Change from baseline to end of study regarding problems in daily living with diabetes as assessed per PAID

Initial information at time of registration:

1. Remission of depression: no longer fulfilling the DSM-IV-TR criteria for depression according to the Structured Clinical Interview Diagnosis (SCID), and depression score on the Hamilton Depression Rating Scale (HAMD) Interview less than or equal to 7
2. Improvement of depression (greater than or equal to 50% reduction on the HAMD-baseline

score)

3. Improved generic Health-Related Quality of Life (HRQoL), per SF-3

4. Decreased problems in daily living with diabetes, per Problem Areas In Diabetes scale (PAID)

### **Completion date**

31/12/2010

## **Eligibility**

### **Key inclusion criteria**

Current inclusion criteria as of 08/05/2008:

1. Type 1 or type 2 diabetes mellitus diagnosed at least 12 months beforehand
2. Insulin treatment for at least the past six months
3. 21 to 69 years of age
4. Poor glycaemic control (HbA1c level greater than 7.5% measured twice within the preceding nine months)
5. Current major depression - Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition (DSM-IV-TR) criteria

Previous inclusion criteria:

1. Type 1 or type 2 diabetes mellitus diagnosed at least 12 months beforehand
2. Insulin treatment for at least the past six months
3. 21 to 65 years of age
4. Poor glycaemic control (HbA1c level >8% measured twice within the preceding nine months)
5. Current major depression - Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition (DSM-IV-TR) criteria

### **Participant type(s)**

Patient

### **Healthy volunteers allowed**

No

### **Age group**

Adult

### **Sex**

All

### **Key exclusion criteria**

1. Clinically significant suicide risk or history of attempted suicide
2. History of schizophrenia or psychotic symptoms
3. Bipolar disorder
4. Organic brain syndrome or dementia
5. Alcohol or substance abuse or dependence in the past 6 months

### **Date of first enrolment**

01/03/2006

### **Date of final enrolment**

31/12/2010

## Locations

### Countries of recruitment

Germany

### Study participating centre

LWL-University Clinic Bochum

Bochum

Germany

44791

## Sponsor information

### Organisation

Ruhr University of Bochum (Germany)

### ROR

<https://ror.org/04tsk2644>

## Funder(s)

### Funder type

Government

### Funder Name

German Federal Ministry of Education and Research (Bundesministerium Für Bildung und Forschung [BMBF]) (Germany) (ref: 01KG0505)

## Results and Publications

### Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
-------------	---------	--------------	------------	----------------	-----------------

<a href="#">Results article</a>	results	01/05/2015	Yes	No
<a href="#">Protocol article</a>	protocol	06/08/2013	Yes	No